An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer

Freidin, Maxim B.; Tay, Andee; Фрейдин, Максим Борисович; Chudasama, Dimple; Nicholson, Andrew G.; Rice, Alexandra; Anikin, Vladimir; Lim, Eric

doi:10.1016/j.lungcan.2014.05.017

Cited by 40 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a multitude devices available on the market, with varying functionality (19)(20)(21)(22)(23)(24)(25) The CTC detection rate by ScreenCell in our study, was higher compared to similar studies looking at patients with early-stage NSCLC. Freidin et al (2014) reported CTC detection rates of 56% and 65% by two separate pathologists using ScreenCell in patients undergoing surgery for early-stage lung cancer in comparison to 78.3% (N=15) and 73.9% (N=14) detection rates in our study (Table II) (26). This could partly be explained by the subjective nature of the method of identification, particularly in the absence of any special or specific antibody stains.…”

Section: Discussionmentioning

confidence: 49%

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Chudasama

Barr

Beeson

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 49%

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Chudasama

Barr

Beeson

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…It is based on a filter that isolates and sorts tumor cells by size. There are 3 different types of device, depending on the downstream analysis: ScreenCell Cyto (molecular techniques that require fixed cells), ScreenCell CC (cell culture), and ScreenCell MB (RNA or DNA analysis) (35,36 ). The main advantages of this system are its low cost, small format, and ease of use.…”

Section: Methods Based On Physical Propertiesmentioning

confidence: 99%

Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation

et al. 2016

View full text Add to dashboard Cite

International audienceBackground: Circulating tumor cells (CTCs) are biomarkers for non-invasively measuring the evolution of tumor genotypes during treatment and disease progression. Recent technical progress has made it possible to detect and characterize CTCs at the single-cell level in blood. Content: Most current methods are based on epithelial cell adhesion molecule (EpCAM) detection, but numerous studies have demonstrated that EpCAM is not a universal marker for CTC detection since it fails to detect both carcinoma cells that undergo epithelial-mesenchymal transition (EMT), and CTCs of mesenchymal origin. Moreover, EpCAM expression has been found in patients with benign diseases. A large proportion of the current studies and reviews about CTCs describe EpCAM based methods, but there are evidences that not all tumor cells can be detected using this marker. Here we describe the most recent EpCAM-independent methods for enriching, isolating and characterizing CTCs, based on physical and biological characteristics, and point out their main advantages and disadvantages.Summary: CTCs offer an opportunity to obtain key biological information required for the development of personalized medicine. However there is no universal marker of these cells. To strengthen the clinical utility of CTCs, it is important to improve existing technologies and develop new, non-EpCAM based systems to enrich and isolate CTCs

show abstract

“…Ò Size, Deforma-bility Filters fixed samples through 8-mm pores, 10e12 wells can process 1 mL each, clusters observed (Chinen et al, 2013;Farace et al, 2011;Hofman et al, 2011;Ilie et al, 2014;Krebs et al, 2012;Pailler et al, 2013;Vona et al, 2000) ScreenCell Ò Hydrophilic surface, fixed/live samples, 7.5/6.5-mm pores (Desitter et al, 2011;Freidin et al, 2014) 2D, Lithography CellSieveä Constructed from a transparent, flexible, non-fluorescent photoresist, 7-mm pores (Adams et al, 2014a(Adams et al, , 2014b(Adams et al, , 2015 Flexible Micro Spring Array (FMSA)…”

Section: D Track-etched Isetmentioning

confidence: 99%

Circulating tumor cell technologies

2016

View full text Add to dashboard Cite

Cancer CTC capture CTC clustersImmunoaffinity enrichment A B S T R A C TCirculating tumor cells, a component of the "liquid biopsy", hold great potential to transform the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of CTCs lies in the ability to detect and isolate these rare cells using methods amenable to downstream characterization and other applications. In this review, we will provide an overview of current technologies used to detect and capture CTCs with brief insights into the workings of individual technologies. We focus on the strategies employed by different platforms and discuss the advantages of each. As our understanding of CTC biology matures, CTC technologies will need to evolve, and we discuss some of the present challenges facing the field in light of recent data encompassing epithelial-to-mesenchymal transition, tumor-initiating cells, and CTC clusters.

show abstract

An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer

Cited by 40 publications

References 13 publications

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation

Circulating tumor cell technologies

Contact Info

Product

Resources

About